Key clinical point: Fremanezumab reduced headache days in patients with chronic or episodic migraine.
Major finding: In patients with chronic migraine, fremanezumab reduced the number of headache days (least-squares mean change = -4.0) compared with placebo (-1.8).
Study details: Subgroup analysis of data from two phase 3 studies - HALO EM and HALO CM - including 186 patients with episodic migraine and 407 patients with chronic migraine.
Disclosures: This study was funded by Teva Pharmaceuticals, Petach Tikva, Israel.
McAllister P et al. AAN 2019. P1.10-011.